Варианты подходов к нефрэктомии у пациентов с терминальной стадией хронической болезни почек, вызванной аутосомно-доминантной поликистозной болезнью почек

Симонов П.А., Фирсов М.А., Арутюнян В.С., Лалетин Д.И., Алексеева Е.А. Варианты подходов к нефрэктомии у пациентов с терминальной стадией хронической болезни почек, вызванной аутосомно-доминантной поликистозной болезнью почек. Consilium Medicum. 2022;24(10):
DOI: 10.26442/20751753.2022.10.201829

© ООО «КОНСИЛИУМ МЕДИКУМ», 2022

________________________________________________

Simonov PA, Firsov MA, Arutunyan VS, Laletin DI, Alekseeva EA. Options for approaches to nephrectomy in patients with end-stage chronic kidney disease caused by autosomal dominant polycystic kidney disease. Consilium Medicum. 2022;24(10): DOI: 10.26442/20751753.2022.10.201829

Читать PDF

Аннотация

Аутосомно-доминантная поликистозная болезнь почек – это распространенное заболевание почек, поражающее все расовые группы во всем мире, занимающее одно из лидирующих мест в структуре урологических заболеваний и формирующее весомый вклад в структуре всех причин, приводящих к терминальной стадии хронической почечной недостаточности, инвалидизируя пациентов данной группы, и, следовательно, приводящее к неизбежности заместительной почечной терапии. Высокоэффективным клиническим способом замещения утраченной функции почек является трансплантация почки. Исходя из того, что число пациентов с данной патологией увеличивается, необходимы поиск и введение четких критериев для наилучшего оказания помощи, принимая во внимание высокую вероятность развития инфекционных осложнений, гематурии, отсутствие или наличие диуреза, артериальной гипертензии у данной категории пациентов. В статье отражены различные методики нефрэктомии у пациентов, страдающих аутосомно-доминантной поликистозной болезнью почек, а также как именно эволюционировали подходы к нефрэктомии. Демонстрируются результаты осложнений, а также выживаемости пациентов и трансплантата в отечественных и иностранных исследованиях, в которых применялась билатеральная или ипсилатеральная нефрэктомия с использованием открытого или лапароскопического доступа до, во время или после трансплантации почки. Предпочтение по праву отдается малоинвазивным методам оперативного лечения. Принимая во внимание и без того сниженные ресурсы организма данных пациентов, следует внимательно избирать объем и метод оперативного лечения в целях обеспечения безопасности, эффективности и минимизации рисков.

Ключевые слова: аутосомно-доминантная поликистозная болезнь почек, билатеральная нефрэктомия, трансплантация почки, лапароскопическая нефрэктомия

________________________________________________

Autosomal-dominant polycystic kidney disease is a common kidney disease that affects all racial groups around the world, occupies one of the leading places in the structure of urological diseases and forms a significant contribution to the structure of all causes leading to the end stage of chronic renal failure, disabling patients in this group and hence leading to the inevitability of renal replacement therapy. A highly effective clinical method for replacing lost kidney function is kidney transplantation. Based on the fact that the number of patients with this pathology is increasing, it is necessary to search for and introduce clear criteria for the best care, taking into account the high likelihood of developing infectious complications, hematuria, the absence or presence of diuresis, arterial hypertension in this category of patients. The article reflects the various methods of nephrectomy in patients suffering from autosomal dominant polycystic kidney disease, as well as how approaches to nephrectomy have evolved. The results of complications, as well as patient and graft survival in domestic and foreign studies, in which bilateral or ipsilateral nephrectomy was used using open or laparoscopic access before, during or after kidney transplantation, are demonstrated. Preference is rightfully given to minimally invasive methods of surgical treatment. Taking into account the already reduced resources of the organism of these patients, the volume and method of surgical treatment should be carefully chosen, taking into account safety, efficacy and risk minimization.

Keywords: autosomal-dominant polycystic kidney disease, bilateral nephrectomy, kidney transplantation, laparoscopic nephrectomy

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Янковой А.Г. Трансплантация почки у больных с урологическими заболеваниями: дис.… д-ра мед. наук. М., 2005 [Iankovoi AG. Transplantatsiia pochki u bol'nykh s urologicheskimi zabolevaniiami: dis.… d-ra med. nauk. Moscow, 2005 (in Russian)].
2. Banaga ASI, Mohammed EB, Siddig RM, et al. Causes of end stage renal failure among haemodialysis patients in Khartoum State/Sudan. BMC Res Notes. 2015;8(1):1-7.
3. Pei Y. Diagnostic approach in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2006;1(5):1108-14.
4. Sarmento LR, Fernandes PFCBC, Pontes MX, et al. Prevalence of clinically validated primary causes of end-stage renal disease (ESRD) in a State Capital in Northeastern Brazil. J Bras Nefrol. 2018;40(2):130-5. DOI:10.1590/2175-8239-jbn-3781 .
5. Sedman A, Bell P, Manco-Johnson M, et al. Autosomal dominant polycystic kidney disease in childhood: a longitudinal study. Kidney Int. 1987;31(4):1000-5.
6. Mitcheson H, Williams G, Castro JE. Clinical aspects of polycystic disease of the kidneys. Br Med J. 1977;1(6070):1196-9..
7. Churchill DN, Bear JC, Morgan J, et al. Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int. 1984;26(2):190-3.
8. Harris PC. 2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery. J Am Soc Nephrol. 2009;20(6):1188-98.
9. Bajwa ZH, Gupta S, Warfield CA, Steinman TI. Pain management in polycystic kidney disease. Kidney Int. 2001;60(5):1631-44.
10. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. New Engl J Med. 2006;354(20):2122-30.
11. Максимова В. Н., Прозорова В. С., Стяжкина С. Н. Трансплантация почки как метод выбора при лечении терминальной стадии хронической почечной недостаточности (обзор литературы). Colloquium-journal. 2019(8-3):22-3 [Maksimova VN, Prozorova VS, Styazkina SN. Transplantation of the kidney as a method of choice in the treatment of a terminal stage of chronic kidney insufficiency (literature review). Colloquium-journal. 2019(8-3):22-3 (in Russian)].
12. Андрусев А.М., Томилина Н.А., Перегудова Н.Г., Шинкарев М.Б. Заместительная почечная терапия хронической болезни почек 5 стадии в Российской Федерации 2015–2109 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. Нефрология и диализ. 2021;23(3):255-329 [Andrusev AM, Tomilina NA, Peregudova NG, Shinkarev MB. Kidney replacement therapy for end stage kidney disease in russian federation, 2015–2019. Russian national kidney replacement therapy registry report of russian public organization of nephrologists “Russian dialysis society”. Nefrologiia i dializ. 2021;23(3):255‑329 (in Russian)].
13. Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006;6:357-63.
14. Grassmann S, Apelt J, Ligneau X, et al. Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: omega-piperidinoalkanamine derivatives. Arch Pharm (Weinheim). 2004;337(10):533–45.
15. Готье С.В., Мойсюк Я.Г., Хомяков С.М., Ибрагимова О.С. Развитие органного донорства и трансплантации в Российской Федерации в 2006–2010 гг. III cообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2011;2:6-20 [Gautier SV, Moysyuk YG, Khomyakov SM, Ibragimova O.S. Progress in organ donation and transplantation in russian federation in 2006–2010. 3rd report of national registry. Russian Journal of Transplantology and Artificial Organs. 2011;13(2):6-20 (in Russian)].
16. Jacquet A, Pallet N, Kessler M, et al. Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int. 2011;24(6):582-7. DOI:10.1111/j.1432-2277.2011.01237.x; PMID: 21352383
17. Roozbeh J, Razmkon AR, Jalaeian H, et al. Outcome of kidney transplantation in patients with polycystic kidney disease: A single center study. Saudi J Kidney Dis Transpl. 2008;19(1):72.
18. Maxeiner A, Bichmann A, Oberländer N, et al. Native nephrectomy before and after renal transplantation in patients with autosomal dominant polycystic kidney disease (ADPKD). J Clin Med. 2019;8(10):1622.
19. Gonçalves S, Guerra J, Santana A, et al. Autosomal-dominant polycystic kidney disease and kidney transplantation: experience of a single center. Transplant Proc. 2009;41(3):887-90.
20. Bhutani G, Astor BC, Mandelbrot DA, et al. Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease. Kidney360. 2021;2(2):312.
21. Argyrou C, Moris D, Vernadakis S. Tailoring the ‘perfect fit’for renal transplant recipients with end-stage polycystic kidney disease: indications and timing of native nephrectomy. In vivo. 2017;31(3):307-12.
22. Дайнеко В.С., Ананьев А.Н., Невирович Е.С., и др. Результаты трансплантации почки пациентам с терминальной почечной недостаточностью, обусловленной аутосомно-доминантным поликистозом почек. Вестник трансплантологии и искусственных органов. 2019;21(2):39-48 [Daineko VS, Ananiev AN, Nevirovich ES, et al. Results of kidney transplantation in patients with end-stage renal failure caused by autosomal dominant polycystic kidney disease. Russian Journal of Transplantology and Artificial Organs. 2019;21(2):39-48 (in Russian)].
23. Fuller TF, Brennan TV, Feng S, et al. End stage polycystic kidney disease: indications and timing of native nephrectomy relative to kidney transplantation. J Urol. 2005;174(6):2284-8.
24. Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008;3(4):1197-204.
25. Bennett AH, Stewart W, Lazarus JM. Bilateral nephrectomy in patients with polycystic renal disease. Surg Gynecol Obstet. 1973;137(5):819-20.
26. Sanfilippo FP, Vaughn WK, Peters TG, et al. Transplantation for polycystic kidney disease. Transplantation. 1983;36(1):54-9.
27. European Renal Best Practice (ERBP) Transplantation guideline development group et al. Guideline. Nephrol Dial Transplant. 2013;28(suppl_2):ii1-71.
28. Oettinger CW, Merrill R, Blanton T, Briggs W. Reduced calcium absorption after nephrectomy in uremic patients. N Engl J Med. 1974;291(9):458-60. DOI:10.1056/NEJM197408292910906
29. Hadimeri H, Norden G, Friman S, Nyberg G. Autosomal dominant polycystic kidney disease in a kidney transplant population. Nephrol Dial Transplant. 1997;12(7):1431-6.
30. Brazda E, Ofner D, Riedmann B, et al. The effect of nephrectomy on the outcome of renal transplantation in patients with polycystic kidney disease. Ann Transplant. 1996;1(2):15-8.
31. Calman KC, Bell PR, Briggs JD, et al. Bilateral nephrectomy prior to renal transplantation. Br J Surg. 1976;63(7):512-6.
32. Sulikowski T, Tejchman K, Zietek Z, et al. Experience with autosomal dominant polycystic kidney disease in patients before and after renal transplantation: a 7-year observation. Transplant Proc. 2009;41(1):177-80.
33. Neeff HP, Pisarski P, Tittelbach-Helmrich D, et al. One hundred consecutive kidney transplantations with simultaneous ipsilateral nephrectomy in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2013;28(2):466-71.
34. Kasiske BL, Ramos EL, Gaston RS, et al. The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol. 1995;6(1):1-34.
35. Chebib FT, Prieto M, Jung Y, et al. Native nephrectomy in renal transplant recipients with autosomal-dominant polycystic kidney disease. Transplant Direct. 2015;1(10).
36. Kramer A, Sausville J, Haririan A, et al. Simultaneous bilateral native nephrectomy and living donor renal transplantation are successful for polycystic kidney disease: the University of Maryland experience. J Urol. 2009;181(2):724-8.
37. Wagner MD, Prather JC, Barry JM. Selective, concurrent bilateral nephrectomies at renal transplantation for autosomal dominant polycystic kidney disease. J Urol. 2007;177(6):2250-4.
38. Glassman DT, Nipkow L, Bartlett ST, Jacobs SC. Bilateral nephrectomy with concomitant renal graft transplantation for autosomal dominant polycystic kidney disease. J Urol. 2000;164(3):661-4.
39. Martin AD, Mekeel KL, Castle EP, et al. Laparoscopic bilateral native nephrectomies with simultaneous kidney transplantation. BJU Int. 2012;110(11c):E1003-7.
40. Kanaan N, Devuyst O, Pirson Y. Renal transplantation in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2014;10(8):455-65.
41. Резник О.Н. Ананьев А.Н., Невирович Е.С., и др. Лапароскопическая нефрэктомия у пациентов с аутосомно-доминантным поликистозом почек. Вестник трансплантологии и искусственных органов. 2016;18(3):50-6 [Reznik ON, Ananiev AN, Nevirovich ES, et al. Laparoscopic nephrectomy in patients with autosomal dominant polycystic kidney disease. Russian Journal of Transplantology and Artificial Organs. 2016;18(3):50-6. (in Russian)].
42. Lipke MC, Bargman V, Milgrom M, Sundaram CP. Limitations of laparoscopy for bilateral nephrectomy for autosomal dominant polycystic kidney disease. J Urol. 2007;177(2):627-31.
43. Abrol N, Bentall A, Torres VE, Prieto M. Simultaneous bilateral laparoscopic nephrectomy with kidney transplantation in patients with ESRD due to ADPKD: A single‐center experience. Am J Transplant. 2021;21(4):1513-24.

________________________________________________

1. Iankovoi AG. Transplantatsiia pochki u bol'nykh s urologicheskimi zabolevaniiami: dis.… d-ra med. nauk. Moscow, 2005 (in Russian).
2. Banaga ASI, Mohammed EB, Siddig RM, et al. Causes of end stage renal failure among haemodialysis patients in Khartoum State/Sudan. BMC Res Notes. 2015;8(1):1-7.
3. Pei Y. Diagnostic approach in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2006;1(5):1108-14.
4. Sarmento LR, Fernandes PFCBC, Pontes MX, et al. Prevalence of clinically validated primary causes of end-stage renal disease (ESRD) in a State Capital in Northeastern Brazil. J Bras Nefrol. 2018;40(2):130-5. DOI:10.1590/2175-8239-jbn-3781 .
5. Sedman A, Bell P, Manco-Johnson M, et al. Autosomal dominant polycystic kidney disease in childhood: a longitudinal study. Kidney Int. 1987;31(4):1000-5.
6. Mitcheson H, Williams G, Castro JE. Clinical aspects of polycystic disease of the kidneys. Br Med J. 1977;1(6070):1196-9..
7. Churchill DN, Bear JC, Morgan J, et al. Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int. 1984;26(2):190-3.
8. Harris PC. 2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery. J Am Soc Nephrol. 2009;20(6):1188-98.
9. Bajwa ZH, Gupta S, Warfield CA, Steinman TI. Pain management in polycystic kidney disease. Kidney Int. 2001;60(5):1631-44.
10. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. New Engl J Med. 2006;354(20):2122-30.
11. Максимова В. Н., Прозорова В. С., Стяжкина С. Н. Трансплантация почки как метод выбора при лечении терминальной стадии хронической почечной недостаточности (обзор литературы). Colloquium-journal. 2019(8-3):22-3 [Maksimova VN, Prozorova VS, Styazkina SN. Transplantation of the kidney as a method of choice in the treatment of a terminal stage of chronic kidney insufficiency (literature review). Colloquium-journal. 2019(8-3):22-3 (in Russian)].
12. Andrusev AM, Tomilina NA, Peregudova NG, Shinkarev MB. Kidney replacement therapy for end stage kidney disease in russian federation, 2015–2019. Russian national kidney replacement therapy registry report of russian public organization of nephrologists “Russian dialysis society”. Nefrologiia i dializ. 2021;23(3):255‑329 (in Russian).
13. Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006;6:357-63.
14. Grassmann S, Apelt J, Ligneau X, et al. Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: omega-piperidinoalkanamine derivatives. Arch Pharm (Weinheim). 2004;337(10):533–45.
15. Gautier SV, Moysyuk YG, Khomyakov SM, Ibragimova O.S. Progress in organ donation and transplantation in russian federation in 2006–2010. 3rd report of national registry. Russian Journal of Transplantology and Artificial Organs. 2011;13(2):6-20 (in Russian).
16. Jacquet A, Pallet N, Kessler M, et al. Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int. 2011;24(6):582-7. DOI:10.1111/j.1432-2277.2011.01237.x; PMID: 21352383
17. Roozbeh J, Razmkon AR, Jalaeian H, et al. Outcome of kidney transplantation in patients with polycystic kidney disease: A single center study. Saudi J Kidney Dis Transpl. 2008;19(1):72.
18. Maxeiner A, Bichmann A, Oberländer N, et al. Native nephrectomy before and after renal transplantation in patients with autosomal dominant polycystic kidney disease (ADPKD). J Clin Med. 2019;8(10):1622.
19. Gonçalves S, Guerra J, Santana A, et al. Autosomal-dominant polycystic kidney disease and kidney transplantation: experience of a single center. Transplant Proc. 2009;41(3):887-90.
20. Bhutani G, Astor BC, Mandelbrot DA, et al. Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease. Kidney360. 2021;2(2):312.
21. Argyrou C, Moris D, Vernadakis S. Tailoring the ‘perfect fit’for renal transplant recipients with end-stage polycystic kidney disease: indications and timing of native nephrectomy. In vivo. 2017;31(3):307-12.
22. Daineko VS, Ananiev AN, Nevirovich ES, et al. Results of kidney transplantation in patients with end-stage renal failure caused by autosomal dominant polycystic kidney disease. Russian Journal of Transplantology and Artificial Organs. 2019;21(2):39-48 (in Russian).
23. Fuller TF, Brennan TV, Feng S, et al. End stage polycystic kidney disease: indications and timing of native nephrectomy relative to kidney transplantation. J Urol. 2005;174(6):2284-8.
24. Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008;3(4):1197-204.
25. Bennett AH, Stewart W, Lazarus JM. Bilateral nephrectomy in patients with polycystic renal disease. Surg Gynecol Obstet. 1973;137(5):819-20.
26. Sanfilippo FP, Vaughn WK, Peters TG, et al. Transplantation for polycystic kidney disease. Transplantation. 1983;36(1):54-9.
27. European Renal Best Practice (ERBP) Transplantation guideline development group et al. Guideline. Nephrol Dial Transplant. 2013;28(suppl_2):ii1-71.
28. Oettinger CW, Merrill R, Blanton T, Briggs W. Reduced calcium absorption after nephrectomy in uremic patients. N Engl J Med. 1974;291(9):458-60. DOI:10.1056/NEJM197408292910906
29. Hadimeri H, Norden G, Friman S, Nyberg G. Autosomal dominant polycystic kidney disease in a kidney transplant population. Nephrol Dial Transplant. 1997;12(7):1431-6.
30. Brazda E, Ofner D, Riedmann B, et al. The effect of nephrectomy on the outcome of renal transplantation in patients with polycystic kidney disease. Ann Transplant. 1996;1(2):15-8.
31. Calman KC, Bell PR, Briggs JD, et al. Bilateral nephrectomy prior to renal transplantation. Br J Surg. 1976;63(7):512-6.
32. Sulikowski T, Tejchman K, Zietek Z, et al. Experience with autosomal dominant polycystic kidney disease in patients before and after renal transplantation: a 7-year observation. Transplant Proc. 2009;41(1):177-80.
33. Neeff HP, Pisarski P, Tittelbach-Helmrich D, et al. One hundred consecutive kidney transplantations with simultaneous ipsilateral nephrectomy in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2013;28(2):466-71.
34. Kasiske BL, Ramos EL, Gaston RS, et al. The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol. 1995;6(1):1-34.
35. Chebib FT, Prieto M, Jung Y, et al. Native nephrectomy in renal transplant recipients with autosomal-dominant polycystic kidney disease. Transplant Direct. 2015;1(10).
36. Kramer A, Sausville J, Haririan A, et al. Simultaneous bilateral native nephrectomy and living donor renal transplantation are successful for polycystic kidney disease: the University of Maryland experience. J Urol. 2009;181(2):724-8.
37. Wagner MD, Prather JC, Barry JM. Selective, concurrent bilateral nephrectomies at renal transplantation for autosomal dominant polycystic kidney disease. J Urol. 2007;177(6):2250-4.
38. Glassman DT, Nipkow L, Bartlett ST, Jacobs SC. Bilateral nephrectomy with concomitant renal graft transplantation for autosomal dominant polycystic kidney disease. J Urol. 2000;164(3):661-4.
39. Martin AD, Mekeel KL, Castle EP, et al. Laparoscopic bilateral native nephrectomies with simultaneous kidney transplantation. BJU Int. 2012;110(11c):E1003-7.
40. Kanaan N, Devuyst O, Pirson Y. Renal transplantation in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2014;10(8):455-65.
41. Reznik ON, Ananiev AN, Nevirovich ES, et al. Laparoscopic nephrectomy in patients with autosomal dominant polycystic kidney disease. Russian Journal of Transplantology and Artificial Organs. 2016;18(3):50-6. (in Russian).
42. Lipke MC, Bargman V, Milgrom M, Sundaram CP. Limitations of laparoscopy for bilateral nephrectomy for autosomal dominant polycystic kidney disease. J Urol. 2007;177(2):627-31.
43. Abrol N, Bentall A, Torres VE, Prieto M. Simultaneous bilateral laparoscopic nephrectomy with kidney transplantation in patients with ESRD due to ADPKD: A single‐center experience. Am J Transplant. 2021;21(4):1513-24.

Авторы

П.А. Симонов*1, М.А. Фирсов1,2, В.С. Арутюнян3, Д.И. Лалетин1,2, Е.А. Алексеева1,2

1 КГБУЗ «Краевая клиническая больница», Красноярск, Россия;
2 ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России, Красноярск, Россия;
3 ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия
*wildsnejok@mail.ru

________________________________________________

Pavel A. Simonov*1, Mikhail A. Firsov1,2, Vagan S. Arutunyan3, Dmitrii I. Laletin1,2, Ekaterina A. Alekseeva1,2

1 Regional Clinical Hospital, Krasnoyarsk, Russia;
2 Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia;
3 Loginov Moscow Clinical Scientific Center, Moscow, Russia
*wildsnejok@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.